Effects of candesartan and perindopril on renal function, TGF-b1 plasma levels and excretion of prostaglandins in stable renal allograft recipients

Gr, Hetzel; Hermsen, Derik; Hohlfeld, Thomas; Rettich, Andreas; Özcan, Filiz; Fußhöller, Andreas; Grabensee, B; Plum, J

doi:10.5414/cnp57296

Cited by 6 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In another uncontrolled series of nine heart recipients, enalapril was associated with stabilization of chronic kidney disease over 2 years of follow‐up (60). In kidney transplant patients, ACE inhibitors and ARBs have been documented to slow progression of chronic allograft nephropathy and reduce circulating levels of the fibrogenic growth factor, TGF‐β (61,62). As calcineurin inhibitor related kidney fibrosis is mediated through induction of TGF‐β, it is likely that the effectiveness of ACE inhibitors and ARBs in retarding progressive renal injury occurs, in part, through disruption of this mechanism.…”

Section: Treatment Of Kidney Disease In Heart and Lung Transplant Recmentioning

confidence: 99%

Kidney Disease After Heart and Lung Transplantation

Bloom

Doyle

2006

American Journal of Transplantation

104

View full text Add to dashboard Cite

Kidney disease is a commonly recognized complication of heart and lung transplantation and is associated with increased morbidity and mortality. While the spectrum of kidney disease in this population is wide-ranging, studies indicate that between 3% and 10% of these patients will ultimately develop endstage renal disease (ESRD). This review examines the risk factors for both acute and chronic kidney injury, with a particular emphasis on the role of calcineurin inhibitor-mediated nephrotoxicity in both these settings. Against the background of current National Kidney Foundation Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines, we have further considered and recommended appropriate strategies for longterm management of kidney disease-related manifestations in heart and lung transplant recipients. Specific aspects addressed include retarding progressive renal injury and minimizing nephrotoxicity, as well as treatment of hypertension, hyperlipidemia and anemia. Finally, for patients in this population with advanced kidney disease, renal replacement therapy options are discussed. Based on the impact of chronic kidney disease on outcomes in both heart and lung recipients, we advocate early referral to a nephrologist for patients displaying evidence of significant renal dysfunction.

show abstract

Section: Treatment Of Kidney Disease In Heart and Lung Transplant Recmentioning

confidence: 99%

Kidney Disease After Heart and Lung Transplantation

Bloom

Doyle

2006

American Journal of Transplantation

104

View full text Add to dashboard Cite

show abstract

“…The use of captopril or enalapril at the time of TBI in these animals resulted in less azotemia, lower blood pressures, decreased proteinuria, and long-term preservation of renal function [86]. ACEI and angiotensin receptor blockers (ARBs) also help reduce inflammation and inflammatory markers and reduce circulating levels of TGF-β1 in patients after transplant [87–90]. These agents have also been shown to slow CKD progression and decrease proteinuria in patients with renal disease from various causes [91, 92].…”

Section: Management Of Ckd After Liver Cardiac Lung and Hsctmentioning

confidence: 99%

Chronic kidney disease after liver, cardiac, lung, heart–lung, and hematopoietic stem cell transplant

Hingorani

2008

Pediatr Nephrol

View full text Add to dashboard Cite

Patient survival after cardiac, liver, and hematopoietic stem cell transplant (HSCT) is improving; however, this survival is limited by substantial pretransplant and treatmentrelated toxicities. A major cause of morbidity and mortality after transplant is chronic kidney disease (CKD). Although the majority of CKD after transplant is attributed to the use of calcineurin inhibitors, various other conditions such as thrombotic microangiopathy, nephrotic syndrome, and focal segmental glomerulosclerosis have been described. Though the immunosuppression used for each of the transplant types, cardiac, liver and HSCT is similar, the risk factors for developing CKD and the CKD severity described in patients after transplant vary. As the indications for transplant and the long-term survival improves for these children, so will the burden of CKD. Nephrologists should be involved early in the pretransplant workup of these patients. Transplant physicians and nephrologists will need to work together to identify those patients at risk of developing CKD early to prevent its development and progression to end-stage renal disease.

show abstract

Strategies to Overcome Biological Barriers to Biosensing

Ward¹,

Duman²

2009

In Vivo Glucose Sensing

View full text Add to dashboard Cite

Effects of candesartan and perindopril on renal function, TGF-b1 plasma levels and excretion of prostaglandins in stable renal allograft recipients

Cited by 6 publications

References 0 publications

Kidney Disease After Heart and Lung Transplantation

Kidney Disease After Heart and Lung Transplantation

Chronic kidney disease after liver, cardiac, lung, heart–lung, and hematopoietic stem cell transplant

Strategies to Overcome Biological Barriers to Biosensing

Contact Info

Product

Resources

About